Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: 1. Major Depressive Disorder Clear all
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT01110902
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 12, 2026, 2:58 AM EDT
Terminated Not applicable Interventional Results available

Study of Respiratory Depression When Using a Hydromorphone Pain Protocol

NCT01784991
View directory record Official record
Conditions
Pain, Respiratory Depression
Interventions
Hydromorphone, Usual care group
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
60 Years to 90 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 12, 2026, 2:58 AM EDT
Terminated Not applicable Interventional Results available

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

NCT01426516
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 12, 2026, 2:58 AM EDT
Completed No phase listed Observational

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

NCT05956483
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Costa Mesa, California • Cromwell, Connecticut • Doral, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 12, 2026, 2:58 AM EDT
Completed No phase listed Observational

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

NCT02474680
View directory record Official record
Conditions
Major Depressive Disorder 1
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

NCT03155503
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SUVN-911, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Sep 12, 2026, 2:58 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

NCT06671977
View directory record Official record
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 12, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

NCT05189977
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Propranolol, Prazosin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Not applicable Interventional

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1

NCT00218556
View directory record Official record
Conditions
Depressive Disorder, Major, Hepatitis C
Interventions
Cognitive behavioral treatment for depression
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 12, 2026, 2:58 AM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 1 Interventional

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

NCT05655507
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Zuranolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Flowood, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 12, 2026, 2:58 AM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 12, 2026, 2:58 AM EDT
Terminated Phase 1 Interventional

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

NCT06618118
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Fosigotifator, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Sherman Oaks, California • Orlando, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

NCT00825019
View directory record Official record
Conditions
Major Depressive Disorders
Interventions
amibegron (SR58611A), placebo, paroxetine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Not applicable Interventional

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

NCT06772987
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Accelerated rTMS treatment
Device
Lead sponsor
NeuroQore Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 12, 2026, 2:58 AM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

NCT07412756
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Brenipatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Moorpark, California • Orange, California • New Haven, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

NCT04711005
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
(2R,6R)-Hydroxynorketamine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 12, 2026, 2:58 AM EDT
Not listed Phase 1 Interventional

Ketamine for Major Depressive Disorder

NCT03721900
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 12, 2026, 2:58 AM EDT
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250614
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Sep 12, 2026, 2:58 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 12, 2026, 2:58 AM EDT
Recruiting No phase listed Observational

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

NCT07528014
View directory record Official record
Conditions
Depressed Mood
Interventions
Not listed
Lead sponsor
Salma Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
La Jolla, California • Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 12, 2026, 2:58 AM EDT